Display options
Cite
Abdallah E, Waked E, Abdelwahab MA. Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility. Kidney Res Clin Pract. 2015;35(1):29-34doi: 10.1016/j.krcp.2015.11.002.
Abdallah, E., Waked, E., & Abdelwahab, M. A. (2016). Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility. Kidney research and clinical practice, 35(1), 29-34. https://doi.org/10.1016/j.krcp.2015.11.002
Abdallah, Emad, et al. "Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility." Kidney research and clinical practice vol. 35,1 (2016): 29-34. doi: https://doi.org/10.1016/j.krcp.2015.11.002
Abdallah E, Waked E, Abdelwahab MA. Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility. Kidney Res Clin Pract. 2016 Mar;35(1):29-34. doi: 10.1016/j.krcp.2015.11.002. Epub 2015 Dec 02. PMID: 27069855; PMCID: PMC4811976.
Copy Download .nbib Format: NLM
Share it on

Kidney Res Clin Pract. 2016 Mar;35(1):29-34. doi: 10.1016/j.krcp.2015.11.002. Epub 2015 Dec 02.

Evaluating the association of interleukin-10 gene promoter -592 A/C polymorphism with lupus nephritis susceptibility.

Kidney research and clinical practice

Emad Abdallah, Emam Waked, Mahmoud A Abdelwahab

Affiliations

  1. Department of Nephrology, Theodor Bilharz Research Institute, Cairo, Egypt.
  2. Department of Medical Biochemistry, Faculty of Medicine, Fayoum University, Faiyum, Egypt.

PMID: 27069855 PMCID: PMC4811976 DOI: 10.1016/j.krcp.2015.11.002

Abstract

BACKGROUND: Interleukin-10 (IL-10) is an important immunoregulatory cytokine. There are few studies evaluating the association between IL-10 and lupus nephritis (LN). The aim of this study was to evaluate the association of IL-10 gene promoter -592 A/C with LN susceptibility.

METHODS: The study was conducted on 84 patients with systemic lupus erythematosus (SLE). Patients were divided into LN group (Group I, 48 patients) and non-LN group (Group II, 36 patients). The -592 A/C polymorphisms in IL-10 promoter gene were determined by polymerase chain reaction and restriction fragment length polymorphism in both groups. IL-10 was determined by enzyme-linked immunosorbent assay. Frequencies of the genotypes were compared between LN and non-LN patients and among LN patients with different pathologic classes.

RESULTS: There was a significant increase in serum level of IL-10 (P = 0.001) in Group I compared with Group II and significant positive correlation between serum IL-10 and SLE disease activity index (r = 0.466, P = 0.001) in Group I. There were no significant differences in the distribution of the IL-10 gene promoter -592 A/C genotypes or the allele frequencies between Groups I and II. There was no significant difference between AC/CC and AA genotypes with SLE disease activity index, proteinuria, hematuria, anti-double-stranded DNA, and IL-10 in Group I. There was no significant difference in the distribution of AC and CC genotypes among different pathologic LN classes.

CONCLUSION: IL-10 suggested to play a role in pathogenesis and development of LN. However, the promoter -592 A/C of IL-10 gene suggested to be not associated with serum IL-10 levels or LN susceptibility. In addition, it appears that promoter -592 A/C of IL-10 gene not associated with LN activity or the pathologic classes of LN.

Keywords: Lupus nephritis; Promoter -592 A/C of interleukin-10 gene; Systemic lupus erythematosus

References

  1. Ann Rheum Dis. 2006 Feb;65(2):209-15 - PubMed
  2. Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):403-12 - PubMed
  3. Arthritis Rheum. 2000 Aug;43(8):1790-800 - PubMed
  4. Arthritis Rheum. 1998 Jun;41(6):1090-5 - PubMed
  5. Arthritis Rheum. 1998 Apr;41(4):596-602 - PubMed
  6. N Engl J Med. 2008 Feb 28;358(9):929-39 - PubMed
  7. J Clin Immunol. 1992 Jul;12(4):239-47 - PubMed
  8. Crit Rev Immunol. 2012;32(1):23-63 - PubMed
  9. J Exp Med. 1991 Nov 1;174(5):1209-20 - PubMed
  10. J Exp Med. 1991 Oct 1;174(4):915-24 - PubMed
  11. J Immunol. 2001 Mar 15;166(6):3915-22 - PubMed
  12. J Exp Med. 1994 Jan 1;179(1):305-10 - PubMed
  13. Curr Opin Rheumatol. 2004 Sep;16(5):513-21 - PubMed
  14. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3 - PubMed
  15. Arthritis Rheum. 1998 Oct;41(10):1714-24 - PubMed
  16. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):854-60 - PubMed
  17. J Immunol. 1992 Feb 15;148(4):1143-8 - PubMed
  18. J Exp Med. 1995 Mar 1;181(3):839-44 - PubMed
  19. Kidney Int. 2004 Feb;65(2):521-30 - PubMed
  20. Arthritis Rheum. 2000 Sep;43(9):1976-81 - PubMed
  21. Ann Rheum Dis. 2009 Feb;68(2):234-7 - PubMed
  22. Autoimmun Rev. 2008 Feb;7(4):317-21 - PubMed
  23. Arthritis Rheum. 1997 Aug;40(8):1429-35 - PubMed
  24. Arthritis Rheum. 2012 Aug;64(8):2677-86 - PubMed
  25. J Immunol. 1993 Aug 1;151(3):1224-34 - PubMed
  26. Springer Semin Immunopathol. 2006 Oct;28(2):119-30 - PubMed
  27. Springer Semin Immunopathol. 2006 Oct;28(2):97-107 - PubMed
  28. Clin Exp Rheumatol. 1998 May-Jun;16(3):283-8 - PubMed
  29. Lancet. 2007 Feb 17;369(9561):587-96 - PubMed
  30. PLoS One. 2013 Jul 23;8(7):e69547 - PubMed
  31. Immunogenetics. 1997;46(2):120-8 - PubMed
  32. Curr Opin Immunol. 2004 Dec;16(6):794-800 - PubMed
  33. J Immunol. 1993 Jun 1;150(11):4754-65 - PubMed

Publication Types